Afoxolaner
Prevention and treatment of flea, tick and certain mite infestations in dogs and cats
- CAS No.
- 1093861-60-9
- Indication Class
- Animal Health
- Patent Expiry
- To be assessed
- Therapeutic Area
- Animal Health
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 4 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| 2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride | 1171331-39-7 | Shared by 2 APIs | |
| 1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone | 1125812-58-9 | — | |
| 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-1-naphthoic acid | 1308362-48-2 | — | |
| 4-acetyl-1-naphthoic acid | 131986-05-5 | — |
Listing Logic · Why It's Worth Listing
A core oral pet parasiticide with good palatability and monthly dosing, often combined with milbemycin oxime, enabling fixed-combination product lines.
Animal Health · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
4 key intermediates available; scale-up and cost control manageable
Product Description
Afoxolaner is a potent isoxazoline ectoparasiticide indicated for the treatment and prevention of flea and tick infestations (Ixodes, Rhipicephalus, Dermacentor) in canines. Its mechanism of action involves the selective antagonism of GABA- and glutamate-gated chloride channels in the invertebrate nervous system, inducing hyperexcitation and fatal paralysis. Characterized by rapid systemic absorption and an extended elimination half-life, Afoxolaner supports a once-monthly oral dosing regimen and is frequently formulated with milbemycin oxime to provide broad-spectrum protection against both ectoparasites and endoparasites.
Supply source: Unibest · Afoxolaner, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.